Bellring Brands LLC vs LOréal: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bellring Brands LLC (BRBR)

Q3 202617 Jun – 11 Aug 2026

▼3

BellRing's profit outlook slashed again on inventory, freight and weak demand

Sales growth questioned as stockpiling, not real demand A law firm is investigating whether BellRing misled investors by calling its sales growth real consumer demand when it was actually customers stocking up, and by downplaying competition. If true, it undermines trust in the company's numbers and could bring legal costs, weighing on the stock.
It questions whether reported sales reflect genuine demand, a core driver of the investment case.
Profit guidance cut twice on inventory and freight costs BellRing lowered its full-year profit forecast to $275-$295 million from $315-$335 million, blaming excess shake-bottle inventory, a bad ingredient from a supplier, and sharply higher freight costs. Profit margins are shrinking, so the stock fell even though sales beat expectations.
This is the main new reason the stock is under pressure: earnings power is falling.
Price increases and new products aim to fix margins Management plans a double-digit price increase on Premier shakes in early 2027, plus cost cuts and two new products to reach new customers. These could restore profits, but price hikes risk scaring off shoppers already facing competition, so the benefit is uncertain.
It shows the company's plan to recover, a real counterweight to the negative profit news.
Valuation reset leaves execution risk unresolved After falling over 50% this year, BellRing trades at 10.2 times forward earnings, well below its historical average. That cheap price may attract buyers, but weak Premier Protein sales momentum and heavy promotions show the company still has to prove it can grow profitably.
It explains why the stock is cheap but not necessarily a bargain, balancing the picture.

July 202617 Jun – 11 Aug 2026

▼3

BellRing's profit outlook slashed again on inventory, freight and weak demand

Sales growth questioned as stockpiling, not real demand A law firm is investigating whether BellRing misled investors by calling its sales growth real consumer demand when it was actually customers stocking up, and by downplaying competition. If true, it undermines trust in the company's numbers and could bring legal costs, weighing on the stock.
It questions whether reported sales reflect genuine demand, a core driver of the investment case.
Profit guidance cut twice on inventory and freight costs BellRing lowered its full-year profit forecast to $275-$295 million from $315-$335 million, blaming excess shake-bottle inventory, a bad ingredient from a supplier, and sharply higher freight costs. Profit margins are shrinking, so the stock fell even though sales beat expectations.
This is the main new reason the stock is under pressure: earnings power is falling.
Price increases and new products aim to fix margins Management plans a double-digit price increase on Premier shakes in early 2027, plus cost cuts and two new products to reach new customers. These could restore profits, but price hikes risk scaring off shoppers already facing competition, so the benefit is uncertain.
It shows the company's plan to recover, a real counterweight to the negative profit news.
Valuation reset leaves execution risk unresolved After falling over 50% this year, BellRing trades at 10.2 times forward earnings, well below its historical average. That cheap price may attract buyers, but weak Premier Protein sales momentum and heavy promotions show the company still has to prove it can grow profitably.
It explains why the stock is cheap but not necessarily a bargain, balancing the picture.

Latest17 Jun – 11 Aug 2026

▼3

BellRing's profit outlook slashed again on inventory, freight and weak demand

Sales growth questioned as stockpiling, not real demand A law firm is investigating whether BellRing misled investors by calling its sales growth real consumer demand when it was actually customers stocking up, and by downplaying competition. If true, it undermines trust in the company's numbers and could bring legal costs, weighing on the stock.
It questions whether reported sales reflect genuine demand, a core driver of the investment case.
Profit guidance cut twice on inventory and freight costs BellRing lowered its full-year profit forecast to $275-$295 million from $315-$335 million, blaming excess shake-bottle inventory, a bad ingredient from a supplier, and sharply higher freight costs. Profit margins are shrinking, so the stock fell even though sales beat expectations.
This is the main new reason the stock is under pressure: earnings power is falling.
Price increases and new products aim to fix margins Management plans a double-digit price increase on Premier shakes in early 2027, plus cost cuts and two new products to reach new customers. These could restore profits, but price hikes risk scaring off shoppers already facing competition, so the benefit is uncertain.
It shows the company's plan to recover, a real counterweight to the negative profit news.
Valuation reset leaves execution risk unresolved After falling over 50% this year, BellRing trades at 10.2 times forward earnings, well below its historical average. That cheap price may attract buyers, but weak Premier Protein sales momentum and heavy promotions show the company still has to prove it can grow profitably.
It explains why the stock is cheap but not necessarily a bargain, balancing the picture.

LOréal S.A. (OR.PA)

Q3 202618 Jun – 30 Jul 2026

▲4

L'Oréal beats forecasts, buys growth, and adds Gucci beauty

H1 results beat expectations with record margin L'Oréal's first-half sales rose 6.5% like-for-like to €23.77bn, with a record 21.3% operating margin. All four divisions grew, led by Professional Products and Dermatological Beauty. Strong profit and broad-based growth support a higher share price.
This is the core earnings event that directly drives investor confidence and valuation.
Q2 sales beat forecasts on haircare and mascara demand Second-quarter like-for-like sales rose 6.3%, beating the 5.7% consensus, with Europe up 6.7% and North America up 5.9%. Luxury missed forecasts but China showed double-digit growth. The beat signals resilient consumer demand despite travel retail weakness.
It confirms the growth trend and shows demand is holding up in key regions.
Gucci beauty license starts early, expanding prestige portfolio Coty will exit its Gucci beauty license a year early, letting L'Oréal begin a 50-year exclusive license from July 2027. L'Oréal covers about 70% of Coty's early redemption costs. This adds a major luxury brand to its prestige lineup.
It is a new, long-term revenue stream that strengthens L'Oréal's luxury division.
Acquires Innovist in India and eyes Armani stake L'Oréal agreed to buy a majority stake in Indian digital-first personal care house Innovist, adding brands like Bare Anatomy. It is also named as a possible buyer of a stake in Giorgio Armani Group. Both moves expand reach in fast-growing markets and prestige.
These deals show management actively deploying capital for future growth.

July 202618 Jun – 30 Jul 2026

▲4

L'Oréal beats forecasts, buys growth, and adds Gucci beauty

H1 results beat expectations with record margin L'Oréal's first-half sales rose 6.5% like-for-like to €23.77bn, with a record 21.3% operating margin. All four divisions grew, led by Professional Products and Dermatological Beauty. Strong profit and broad-based growth support a higher share price.
This is the core earnings event that directly drives investor confidence and valuation.
Q2 sales beat forecasts on haircare and mascara demand Second-quarter like-for-like sales rose 6.3%, beating the 5.7% consensus, with Europe up 6.7% and North America up 5.9%. Luxury missed forecasts but China showed double-digit growth. The beat signals resilient consumer demand despite travel retail weakness.
It confirms the growth trend and shows demand is holding up in key regions.
Gucci beauty license starts early, expanding prestige portfolio Coty will exit its Gucci beauty license a year early, letting L'Oréal begin a 50-year exclusive license from July 2027. L'Oréal covers about 70% of Coty's early redemption costs. This adds a major luxury brand to its prestige lineup.
It is a new, long-term revenue stream that strengthens L'Oréal's luxury division.
Acquires Innovist in India and eyes Armani stake L'Oréal agreed to buy a majority stake in Indian digital-first personal care house Innovist, adding brands like Bare Anatomy. It is also named as a possible buyer of a stake in Giorgio Armani Group. Both moves expand reach in fast-growing markets and prestige.
These deals show management actively deploying capital for future growth.

Latest18 Jun – 30 Jul 2026

▲4

L'Oréal beats forecasts, buys growth, and adds Gucci beauty

H1 results beat expectations with record margin L'Oréal's first-half sales rose 6.5% like-for-like to €23.77bn, with a record 21.3% operating margin. All four divisions grew, led by Professional Products and Dermatological Beauty. Strong profit and broad-based growth support a higher share price.
This is the core earnings event that directly drives investor confidence and valuation.
Q2 sales beat forecasts on haircare and mascara demand Second-quarter like-for-like sales rose 6.3%, beating the 5.7% consensus, with Europe up 6.7% and North America up 5.9%. Luxury missed forecasts but China showed double-digit growth. The beat signals resilient consumer demand despite travel retail weakness.
It confirms the growth trend and shows demand is holding up in key regions.
Gucci beauty license starts early, expanding prestige portfolio Coty will exit its Gucci beauty license a year early, letting L'Oréal begin a 50-year exclusive license from July 2027. L'Oréal covers about 70% of Coty's early redemption costs. This adds a major luxury brand to its prestige lineup.
It is a new, long-term revenue stream that strengthens L'Oréal's luxury division.
Acquires Innovist in India and eyes Armani stake L'Oréal agreed to buy a majority stake in Indian digital-first personal care house Innovist, adding brands like Bare Anatomy. It is also named as a possible buyer of a stake in Giorgio Armani Group. Both moves expand reach in fast-growing markets and prestige.
These deals show management actively deploying capital for future growth.